Kleresca® Acne Treatment is a new, clinically proven alternative to traditional therapies for people with all types of acne vulgaris.
Acne is the most common of skin diseases and affects up to 85 per cent of Australians aged 15-24, and it can also persist into adulthood.1 Even after the skin has improved, the physical and emotional scarring of acne can be difficult .2, 3, 4-7
For many people, conventional acne treatments can pose a range of challenges from not working, to skin irritation8-11 and serious side effects.9, 11-15 Now, Australian’s have access to Kleresca®, a new treatment for acne vulgaris approved by the Therapeutic Goods Administration (TGA).
Clinically proven and offering high safety and efficacy, Kleresca® Acne Treatment has in a clinical trial been shown to provide nine out of 10 (89%) patients with an improvement in their acne severity and one in three patients the chance to reach clear or almost clear skin.16, 17
Unlike other treatments, Kleresca® Acne Treatment uses BioPhotonics - a new, unique light conversion system designed to stimulate the skin and improve complexion18-23 to treat acne and reduce the signs of scarring. The treatment uses a high intensity, in-clinic light device together with a photo converter gel to kill bacteria in the skin and initiate healing. 18-23
“Living with acne can have a big impact on a person’s confidence, putting them at greater risk of social anxiety and possibly even depression,” says Dr John Sullivan, Dermatologist at Holdsworth House Dermatology, Sydney.
“Many acne patients are frustrated and still have an unmet need, so they are searching for new, alternative treatments to help improve their skin. Kleresca® represents a significant advancement as an innovative new treatment option, which is a reassuring alternative to oral treatments. Kleresca® targets visible acne lesions, but also has prolonged benefits helping to prevent the formation of new lesions.”
As the deeper layers of the skin respond, Kleresca® Acne Treatment produces long-lasting and noticeable improvements to the skin even after the treatment has ended.22 In clinical trials, 92% of patients who were followed up after the initial 12 week duration, retained their results for at least six months.17, 22
Natalie Walker, who recently completed a course of Kleresca® Acne Treatment, is all too aware of the effect acne and acne scarring can have on a person’s quality of life.
“It began with a few spots in April 2015 and it just got progressively worse. I’ve tried many treatments with varying results and, in some cases, side effects, which I struggled with.”
“Acne has affected my confidence both professionally and socially because I have been so conscious of the condition and the scarring. When you finally see results, it’s such a confidence boost. I feel like the best version of myself and don’t want to go back.”
Patients are required to have treatments twice a week for 6 weeks. Improvement to the skin can be expected as the deeper layers respond, with skin repair occurring during the course of the treatment and after the treatment has ended.22
Clinical data for Kleresca® has been accepted for publication in the International Journal of Dermatology.
Kleresca® is available through certified Kleresca® dermatology clinics. Further information on Kleresca® as well as clinics near you, can be found online: www.kleresca.com.au
P +61 (0) 2 9994 4489 M +61 (0) 456 022 974
1. Acne.org.au, All About Acne, Who Gets Acne, June 2016. http://www.acne.org.au/content_common/pg-who-gets-acne-causes.seo
2. Suh DH, Kwon HH. What’s new in the physiopathology of acne. BJD 2015 Jan 24. doi: 10.1111/bjd.13634. [Epub ahead of print]
3. Bhate K, Williams HC. Epidemiology of acne vulgaris. BJD 2013;168:474-485
4. Tan JKL, Bhate K. A global perspective on the epidemiology of acne. BJD 2015 Jan 17. doi: 10.1111/bjd.13462. [Epub ahead of print]
5. O’Daniel, T. G. Multimodal management of atrophic acne scarring in the aging face. Aesthetic Plast. Surg. 35, 1143–50 (2011)
6. Bock, O., Schmid-Ott, G., Malewski, P. & Mrowietz, U. Quality of life of patients with keloid and hypertrophic scarring. Arch. Dermatol. Res. 297, 433–8 (2006)
7. Cotterill, J. A. & Cunliffe, W. J. Suicide in dermatological patients. Br. J. Dermatol. 137, 246–50 (1997)
8. Ozolins, M. et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised con-trolled trial. Lancet 364, 2188–95
9. Thielitz, A. & Gollnick, H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am. J. Clin. Dermatol. 9, 369–81 (2008)
10. Hamilton, F. L. et al. Laser and other light therapies for the treatment of acne vul-garis: systematic review. Br. J. Dermatol. 160, 1273–85 (2009)
11. Sakamoto, F. H., Lopes, J. D. & Anderson, R. R. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part I. Acne vulgaris: when and why consider photodynamic therapy? J. Am. Acad. Dermatol. 63, 183–93; quiz 193–4 (2010)
12. James, W. D. Clinical practice. Acne. N. Engl. J. Med. 352, 1463–72 (2005).
13. McManus, P. & Iheanacho, I. Don’t use minocycline as first line oral antibiotic in acne. BMJ 334, 154 (2007)
14. Roche Products Limited. Roaccutane 10mg Soft Capsules summary of product characteristics. (2012). at
15. Zheng, W. et al. Evidence-based review of photodynamic therapy in the treat-ment of acne. Eur. J. Dermatol. 24, 444–56
16. Antoniou, C. & et al. (in press) A multicenter, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assisted blue light photo-therapy for the treatment of acne. International Journal of Dermatology. (Ac-cepted for publication January 2016)
17. Proportion of patients with ≥ 1IGA grades decrease from baseline to week 12
18. PCL-K1005-001-11. LEO Pharma – Data on file
19. In vitro release test. LEO Pharma – Data on file
20. Kleresca® Acne Treatment Instruction for Use
21. Kleresca® Skin Rejuvenation Instruction for Use
22. Antoniou, C. & et al. Extension trial. LEO Pharma – Data on file. (2013)
23. Endothelial cell study. LEO Pharma – Data on file.
24. Eisenbud, D. E. Oxygen in wound healing: nutrient, antibiotic, signaling molecule, and therapeutic agent. Clin. Plast. Surg. 39, 293–310 (2012)
25. SKR1. LEO Pharma – Data on file